About Five Prime Therapeutics
Five Prime Therapeutics is a Healthcare company based in San Francisco (United States) founded in 2002, and was acquired by Amgen in March 2021. Antibodies for cancer and inflammatory diseases treatment are developed. Five Prime Therapeutics has raised $154.47 million across 14 funding rounds from investors including Amgen, Kleiner Perkins and TPG. The company has 69 employees. Five Prime Therapeutics offers products and services including Biologic Medicines. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is FIVE PRIME THERAPEUTICS, INC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Five Prime Therapeutics was founded in 2002 in San Francisco, United States, within the biotechnology sector. Antibodies and drug candidates are developed by the company for cancer and inflammatory disease treatments. Operations focus on inhibitors like Cabiralizumab (FPA008), which targets CSF1R for tumors and pigmented villonodular synovitis. Additional candidates include FPA144 for FGFR2b-related conditions and FP-1039 for gastric cancer and mesothelioma. Research is conducted from the U.S. base.
- Headquarters San Francisco, United States
- Employees 69
- Stage Acquired
- SectorsHealthcare
- Website fiveprime.com
- Social LinkedIn
- Acquired by Amgen (Mar 2021)
- Legal Name Five Prime Therapeutics, Inc.
- Annual Revenue$13.18 M (USD)-11as on Dec 31, 2020
- Net Profit-$84.33 M (USD)39as on Dec 31, 2020
- EBITDA-$92.87 M (USD)35as on Dec 31, 2020
- Total Equity Funding$154.47M (USD)
in 14 rounds
- Latest Funding Round$115M (USD), Post-IPO
Jan 2018
- InvestorsAmgen
& 10 more
- Employee Count69
- Acquired byAmgen
(Mar 2021)
Products & Services of Five Prime Therapeutics
Five Prime Therapeutics offers a comprehensive portfolio of products and services, including Biologic Medicines.
Treatments for serious illnesses using biologic technology and research
Funding Insights of Five Prime Therapeutics
Five Prime Therapeutics has successfully raised a total of $154.47M across 14 strategic funding rounds. The most recent funding activity was a Post-IPO round of $115 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $154.47M
- Total Rounds 14
- Last Round Post-IPO — $115M
- First Round $18.13M
(May 2002)
- Investors Count 10
Latest 10 of 14 funding rounds of Five Prime Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2018 | $115M | Post-IPO | – | – | – |
| Jan 2015 | $84M | Post-IPO | – | – | – |
| Mar 2014 | $21.04M | Post-IPO | – | – | – |
| Apr 2012 | $10M | Series D | – | – | – |
| Sep 2010 | $7.5M | Series D | – | – | – |
| May 2010 | $1M | Series D | – | – | |
| Jun 2008 | $40.28M | Series D | – | – | – |
| Dec 2006 | $11M | Series C | – | – | – |
| Feb 2005 | $45M | Series C | – | – | |
| Jan 2004 | $9.5M | Series B | – | – | – |
11 investors in total: 11 institutional.
Investors in Five Prime Therapeutics
Five Prime Therapeutics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Amgen, Kleiner Perkins and TPG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
VC firm making investment in early stage startups in the US | atvcapital.com | Menlo Park, United States | ||
| healthcap.eu | ||||
A boutique investment house focused on capital preservation and growth. | 1972 | diamondcapital.net | Geneva, Switzerland | |
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Foundation fund focused on the eradication of multiple sclerosis | 1946 | nationalmssociety.org | Denver, United States | |
Wellcome is a global charitable foundation focused on health research. | wellcome.ac.uk | London, United Kingdom | ||
Serves as a government agency dedicated to fostering business development and growth in Singapore. | 1961 | edb.gov.sg | Singapore, Singapore |
Investor details for Five Prime Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Five Prime Therapeutics
1108 people are tracked at Five Prime Therapeutics (431 in leadership, 47 in board & advisors, 630 in team); the tracked headcount is 69.
| Name | Role | Group |
|---|---|---|
Seamus Lyons | Sr. Director Manufacturing | Leadership |
Alma Holden | Associate Director Validation | Leadership |
Francisco J Aguado-Rodriguez | Director Of Quality - Data Integrity And Ops Management Review GPO | Leadership |
Vivian Tu | Senior Director, Competitive Intelligence | Leadership |
Amro Essmat | Director , Quality - Regional Quality Head TMEA - Turkey, Middle East & Africa At Amgen | Leadership |
Miriam O'Sullivan | Executive Director Plant Manager | Leadership |
Mara Wachholder | Director, Treasury | Leadership |
Thiago Pastore | Human Resources Director, Brazil | Leadership |
Chris Pacheco | Director Manufacturing | Leadership |
Aditya Tulsyan | Associate Director Data Sciences, Operations | Leadership |
Andreas Reichelt | Senior Director Contract Manufacturing | Leadership |
Laura Cooke | Program Management Executive Director | Enterprise Transformation | Leadership |
Ned Endler | Executive Director US Trade, Channel Strategy And Execution | Leadership |
Amy Belisle | Associate Director Quality | Leadership |
Susie Tappouni | Head of Corporate Affairs | Leadership |
Kim Worrell | Associate Director HR Systems & Solutions | Leadership |
Jessica Vargas | Director, HR Business Partner | Leadership |
Mark Corder | Senior Director | Leadership |
Tara U. | Director, Global Corporate Affairs, Operations | Leadership |
Elena Pakhomov | Executive Director Of Sales | Leadership |
1088 more people are available in the full profile.
Complete people profiles for Five Prime Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Five Prime Therapeutics
5 dated milestones of Five Prime Therapeutics across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Five Prime Therapeutics is founded.
- Funding First funding round of $18.1M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $115.0M.
- Exit Acquired by Amgen.
Competitors of Five Prime Therapeutics
Five Prime Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Five Prime Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Five Prime Therapeutics
Websites that share an audience with Five Prime Therapeutics (fiveprime.com).
Websites whose visitors overlap most with Five Prime Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| oncomed.com | 100% | View details | |||
| portola.com | 91% | View details | |||
| fatetherapeutics.com | 83% | 9.3K | #2,481,408 | View details | |
| acceleronpharma.com | 76% | View details | |||
| veracyte.com | 73% | 53.7K | #739,418 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Five Prime Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Five Prime Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Five Prime Therapeutics
Complete news archive for Five Prime Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Five Prime Therapeutics
Five Prime Therapeutics was founded in 2002.
Five Prime Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Five Prime Therapeutics is a funded company, having raised a total of $154.47M across 14 funding rounds to date. The company's 1st funding round was a Series B of $9.5M, raised on May 2002.
Five Prime Therapeutics has 69 employees.
Annual revenue of Five Prime Therapeutics is $13.18M as on Dec 31, 2020.
Five Prime Therapeutics was founded in 2002 in San Francisco, United States, within the biotechnology sector. Antibodies and drug candidates are developed by the company for cancer and inflammatory disease treatments. Operations focus on inhibitors like Cabiralizumab (FPA008), which targets CSF1R for tumors and pigmented villonodular synovitis. Additional candidates include FPA144 for FGFR2b-related conditions and FP-1039 for gastric cancer and mesothelioma. Research is conducted from the U.S. base.
Five Prime Therapeutics offers Biologic Medicines.
Five Prime Therapeutics has 11 investors. Key investors include Amgen, Kleiner Perkins, TPG, National MS Society, and Domain Associates.
Five Prime Therapeutics operates through Five Prime Therapeutics, Inc..
Yes. Five Prime Therapeutics was acquired by Amgen in March 2021.